ColorTokens Slashes Federal Compliance Timelines and Enhances Container Security with RapidFort
RapidFort, the fastest growing cybersecurity company securing the global software supply chain, has partnered with ColorTokens Inc., a pioneer in Zero Trust security and leader in microsegmentation, to strengthen its containerized infrastructure security and optimize its federal compliance efforts. By leveraging RapidFort's platform, ColorTokens notably reduced its attack surface by 77%, minimizing its security risks and improving security operations.
'RapidFort has measurably strengthened the security of both our cloud‑hosted SaaS platform and our on‑premise product,' said Harish Akali, CTO of ColorTokens, 'It's hardened container images, continuous scanning, and clear remediation guidance have cut our vulnerability backlog and supplied the evidence we needed to fast‑track FedRAMP, IRAP, and other certification audits.'
Like many organizations who enter the federal marketplace, ColorTokens was challenged by diverse third-party base images and complex DevSecOps workflows. The constant need to maintain stringent federal compliance standards, including FIPS and STIG, required a solution that would reduce vulnerabilities without overburdening engineering resources.
RapidFort helped ColorTokens address these challenges by:
'Far too often, organizations must divert critical resources to remediate vulnerabilities and meet compliance requirements, rather than advancing core business priorities,' said Mehran Farimani, CEO of RapidFort. 'By leveraging the RapidFort platform to optimize vulnerability management and minimize their security risks, ColorTokens was able to secure their software faster and with less strain on their teams, reducing the burden of meeting stringent federal compliance requirements.'
RapidFort, already available through Platform One, Tradewind Marketplace, AWS Marketplace, Microsoft Azure Marketplace, Google Cloud Marketplace, and Carahsoft, provides a reliable and efficient pathway for organizations looking to enter the federal marketplace and drive growth in the government sector. For more information about the RapidFort platform, please visit: https://www.rapidfort.com/
About RapidFort
RapidFort offers a cybersecurity platform that streamlines and secures modern infrastructure. Their innovative approach allows organizations to continuously monitor and minimize their software attack surface, ultimately improving their security posture and operational efficiency. RapidFort empowers development and security teams with a free tier and free community images, making it easy to get started with secure software development. Learn more about RapidFort at https://www.rapidfort.com/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250514023785/en/
CONTACT: Cole Christy
LaunchTech Communications
619-972-9836
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SOFTWARE INTERNET DATA MANAGEMENT TECHNOLOGY LOGISTICS/SUPPLY CHAIN MANAGEMENT TRANSPORT OTHER TECHNOLOGY SECURITY
SOURCE: RapidFort
Copyright Business Wire 2025.
PUB: 05/14/2025 09:30 AM/DISC: 05/14/2025 09:31 AM
http://www.businesswire.com/news/home/20250514023785/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Final Days: Don't Miss Tineco's Best Deals of the Year!
PARIS--(BUSINESS WIRE)--Summer is in full swing... and so are the Tineco deals — but not for much longer! Only a few days remain to take advantage of the best prices of the year on the brand's smart cleaning appliances. Featuring premium design, advanced technology, and exceptional performance, Tineco's high-end vacuums and floor washers are built to simplify your routine and deliver a truly effortless clean. Enjoy these exclusive Prime Day offers until July 11, 2025 on the Tineco Amazon Store, and don't forget to unlock an extra 6% discount with the promo code TINPRIME25. Original Price: €699 | Prime Day: €419 Designed to clean effortlessly under low furniture, this floor washer combines power, long runtime, and maneuverability. With its 180° Stretch technology and ultra-slim cleaning head, no spot is out of reach. Original Price: €599 | Prime Day: €349 Compact, agile, and powerful — the perfect everyday cleaning solution. Lightweight and easy to store, it's ideal for tight spaces and quick cleanups. FLOOR ONE S9 Artist Original Price: €899 | Prime Day: €599 Tineco's flagship model, crafted for a premium clean. It vacuums and washes in one seamless pass, automatically detects dirt, and self-cleans after each use. A must-have for spotless floors without the effort. PURE ONE STATION 5 Plus Original Price: €459 | Prime Day: €349 This stick vacuum stands out with its intelligent 3-in-1 self-cleaning station. It charges, empties, and washes itself — always clean, always ready. CARPET ONE Cruiser Original Price: €699 | Prime Day: €559 The ultimate carpet cleaner, delivering powerful suction and fast drying with PowerDry™ technology. Deep cleaning with no compromises. These exclusive offers are available on Amazon until July 11, 2025. About Tineco Tineco ('tin-co') was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 19.5 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit
Business Wire
28 minutes ago
- Business Wire
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor (PR) diseases, which are a subgroup of inherited retinal disorders that includes retinitis pigmentosa and cone-rod dystrophy. 'The initiation of the CLARICO trial represents a key milestone for the OpCT-001 program,' said Amit Rakhit, MD, MBA, BlueRock's Chief Development and Medical Officer. 'We believe OpCT-001 holds significant promise as a novel therapeutic approach for restoring vision in people living with primary photoreceptor diseases, and we look forward to assessing its safety and tolerability profile as we advance this important program in our pipeline.' CLARICO is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor disease. Phase 1 will focus on safety and includes a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups. 'We aim to transform treatment options for patients facing irreversible vision loss. OpCT-001, our investigational iPSC-derived cell therapy, has the potential to restore vision for individuals with primary photoreceptor disease,' said Christian Rommel, Executive Vice President and Global Head of Research and Development of the Pharmaceuticals Division at Bayer. 'We are excited to announce the first patient in the CLARICO trial, the first-ever clinical trial for an iPSC-derived treatment in this field.' Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in both children and adults. OpCT-001 aims to restore vision in patients with primary photoreceptor diseases by replacing degenerated cells in the retina with functional cells. Limited treatment options currently exist for treating primary photoreceptor diseases which affect an estimated 110,000 people in the U.S. 1 OpCT-001 is an investigational cell therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated. About CLARICO CLARICO is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups. Phase 1 will include 4 planned dose levels to be administered across 4 cohorts (Cohorts 1 through 4). Dose escalation in Phase 1 will be conducted using a standard 3+3 scheme in which a total of 12 to 24 legally blind participants (~3 to 6 per cohort) will receive OpCT-001. Phase 2 is planned to enroll a maximum of 15 participants in 2 cohorts (Cohorts 5 and 6) to evaluate 2 dose levels of OpCT-001 that will be selected based on Phase 1 safety and tolerability data. Phase 2 participants will be randomized 1:1 to either Cohort 5 or Cohort 6. Phase 2 participants and the investigator/study site personnel outside of the surgical team will be masked to OpCT-001 dose assignments. Further details of the trial can be found at (NCT06789445). About BlueRock Therapeutics LP BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson's disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. Bemdaneprocel has RMAT (Regenerative Medicine Advanced Therapy) and Fast Track designation from the US FDA (Food and Drug Administration) and is being tested in a Phase 3 clinical trial, exPDite-2. OpCT-001 has Fast Track designation from the FDA and is being tested in a Phase 1 clinical trial, Clarico. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to ime (2025-0082E) Forward-Looking Statements BlueRock Therapeutics Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'plan,' and 'intend,' among others. These forward-looking statements are based on BlueRock's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the initiation, timing, progress, activities, goals and reporting of results of any preclinical programs and clinical trials and research and development programs, the potential benefits, timing and future operation of the agreements with FUJIFILM Cellular Dynamics and Opsis Therapeutics, the ability to advance therapies into, and successfully initiate, enroll and complete clinical trials, the potential clinical utility of product candidates, the regulatory pathway of, and the timing or likelihood of any regulatory filings and approvals for, any product candidates, and the ability to, and extent of, potentially commercializing any product candidate, are forward looking. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of BlueRock's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Business Wire
39 minutes ago
- Business Wire
Construction of the Receiving-End Converter Station of State Grid Corporation of China UHVDC Electricity Transmission Project in the Northeast Region of Brazil Started
BEIJING--(BUSINESS WIRE)--On the morning of June 30th, local time in Brazil, the construction of the receiving-end Silvânia (GO) Converter Station of the ±800 kV ultra-high voltage direct-current electricity transmission project in the Northeast region of Brazil (the "UHVDC electricity transmission project in the Northeast region of Brazil") implemented by State Grid Brazil Holding, a subsidiary of State Grid Corporation of China, started. UHVDC electricity transmission project in the Northeast region of Brazil is the largest power transmission concession project in Brazil's history and also the largest infrastructure construction project in Brazil in recent years. This is the third UHVDC transmission project invested, constructed and operated overseas by State Grid Corporation of China, following Brazil Belo Monte UHV transmission Phase I and phase II project. The project will adopt China's advanced and mature ultra-high voltage direct current transmission technology, which will play an important role in promoting the consumption of clean energy in northeastern Brazil and improving the safe and reliable operation of Brazil's power grid. The project is of great significance in serving the sustainable economic and social development of Brazil, deepening the mutually beneficial and win-win cooperation between China and Brazil, pushing the China-Brazil energy and power cooperation to a new level, opening a new "golden fifty years" of China-Brazil relations and building a China-Brazil community with a shared future. The project includes the construction of 1,468 km (912 miles) of ±800-kV UHV DC transmission lines, converter stations at both ends, and supporting 500kV AC infrastructure, with a rated transmission capacity of 5,000 MW. It will integrate and deliver clean energy (wind, solar, and hydro) from northeastern and northern Brazil, traversing the states of Maranhão, Tocantins, and Goiás to supply approximately 12 million people in regions including the capital Brasília. In December 2023, State Grid Corporation of China secured the project as the sole successful bidder. By April 2024, the company signed a concession agreement with Agência Nacional de Energia Elétrica (ANEEL) and immediately commenced preliminary preparations. After 15 months of environmental licensing and assessment, the receiving-end Silvânia converter station has met all requirements for construction initiation. Scheduled for full completion and operation in 2029, the project holds a 30-year concession term.
